Bausch + Lomb/$BLCO
1D1W1MYTD1Y5YMAX
Capital at risk
About Bausch + Lomb
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
- Ticker
- $BLCO
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 13,000
- Headquarters
- Vaughan, Canada
- Website
- www.bausch.com
Bausch + Lomb Metrics
BasicAdvanced
$6.2B
-
-$0.48
0.55
-
Price and volume
Market cap
$6.2B
Beta
0.55
52-week high
$18.92
52-week low
$13.77
Average daily volume
382K
Financial strength
Current ratio
1.546
Quick ratio
0.812
Long term debt to equity
0.787
Total debt to equity
0.794
Interest coverage (TTM)
0.85%
Profitability
EBITDA (TTM)
816
Gross margin (TTM)
61.44%
Net profit margin (TTM)
-3.21%
Operating margin (TTM)
7.61%
Effective tax rate (TTM)
-150.77%
Revenue per employee (TTM)
$410,000
Management effectiveness
Return on assets (TTM)
1.50%
Return on equity (TTM)
-2.52%
Valuation
Price to revenue (TTM)
1.15
Price to book
0.95
Price to tangible book (TTM)
-4.01
Price to free cash flow (TTM)
44.679
Free cash flow yield (TTM)
2.24%
Free cash flow per share (TTM)
0.386
Growth
Revenue change (TTM)
8.85%
Earnings per share change (TTM)
-38.45%
3-year revenue growth (CAGR)
10.89%
3-year earnings per share growth (CAGR)
6.13%
Bulls say / Bears say
Q2 2026 showed broad-based momentum: revenue increased 9% year over year, with Vision Care, Surgical and Pharmaceuticals growing 4%, 19% and 15%, respectively, prompting the company to raise full-year guidance. (Bausch + Lomb)
Pharmaceuticals is emerging as a strong growth engine, with Q2 revenue up 15% and branded MIEBO and XIIDRA specifically identified as key contributors; Q1 pharmaceutical revenue had also increased 14%. (Bausch + Lomb)
Operating leverage and cash generation are improving: Q2 adjusted EBITDA excluding acquired IPR&D rose 28% to $246 million, operating cash flow reached $153 million, and full-year adjusted EBITDA guidance was raised to $1.025–$1.075 billion. (Bausch + Lomb)
Bausch + Lomb remains GAAP-unprofitable: it reported a $14 million net loss in Q2 2026 and an $80 million net loss for the first half, despite positive adjusted earnings. (SEC)
Leverage remains a material constraint, with $5.13 billion of gross long-term debt, a 7.43% weighted-average stated interest rate, and $1.44 billion of scheduled debt maturities in 2028. (SEC)
The improved outlook depends substantially on non-GAAP performance and assumptions around tariffs, interest rates, foreign exchange and operating execution; the company does not reconcile its forward adjusted-EBITDA guidance to GAAP earnings. (Bausch + Lomb)
Data summarised monthly by Lightyear AI. Last updated on 10 Sept 2026.
Upcoming events
No upcoming events
Bausch + Lomb News
AllArticlesVideos
Funds containing Bausch + Lomb
Fund name | Fund size | $BLCO weighting |
|---|---|---|
iShares Ageing Population€AGED | €822M | 0.06% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.